Recent Reports

Evidence report on anti-androgen drugs for high risk prostate cancer. This report will serve as the basis for discussion during a public meeting of Midwest CEPAC in September 2018.

View More on this Topic

ICER’s Draft Evidence Report, open to public comment until September 20, 2018. For more information on submitting a public comment, please visit our stakeholder engagement page.

View More on this Topic

ICER’s Draft Evidence Report on treatments for hereditary transthyretin-related amyloidosis, open to public comment until August 17, 2018 at 5pm ET. For more information on submitting a public comment, please visit our stakeholder engagement page.

View More on this Topic



Materials

ICER

2020 Value Assessment Framework: Patient Input Guide

ICER

2020 Value Assessment Framework: Initiative Announcement

CTAF

Peanut Allergy: Meeting Agenda

New England CEPAC

Diabetes: Stakeholder List

New England CEPAC

Diabetes: Draft Scoping Document

CTAF

Peanut Allergy: Draft Voting Questions

ICER

The QALY: Rewarding the Care That Most Improves Patients’ Lives

New England CEPAC

SMA: Report-at-a-Glance

CTAF

RA Update: Open Input Period

CTAF

RA Update: Draft Scoping Document

CTAF

RA Update: Stakeholder List

CTAF

RA Update: Public Comment on Draft Scoping Document